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http://dx.doi.org/10.1016/j.ccr.2014.06.005SUMMARYTo understand the relationships between the non-GCIMP glioblastoma (GBM) subgroups, we performed
mathematical modeling to predict the temporal sequence of driver events during tumorigenesis. The most
common order of evolutionary events is 1) chromosome (chr) 7 gain and chr10 loss, followed by 2) CDKN2A
loss and/or TP53mutation, and 3) alterations canonical for specific subtypes. We then developed a compu-
tational methodology to identify drivers of broad copy number changes, identifying PDGFA (chr7) and PTEN
(chr10) as driving initial nondisjunction events. These predictions were validated using mouse modeling,
showing that PDGFA is sufficient to induce proneural-like gliomas and that additional NF1 loss converts pro-
neural to the mesenchymal subtype. Our findings suggest that most non-GCIMP mesenchymal GBMs arise
as, and evolve from, a proneural-like precursor.INTRODUCTION
Glioblastomas (GBMs) are the most common and malignant
CNS neoplasms and arise initially as grade 4 tumors (primary
GBM) or evolve from lower-grade gliomas (secondary GBM).
Deep molecular analyses of primary GBMs have divided them
into four classes: proneural (PN), mesenchymal (MES), classical
(CL), and neural (NL) (Brennan et al., 2009; Phillips et al., 2006;
Verhaak et al., 2010). However, in some cases, the division is
blurred in that a sample might show patterns of more than one
subtype (Brennan et al., 2009; Phillips et al., 2006; Sottoriva
et al., 2013; Verhaak et al., 2010). These subclasses can be asso-Significance
Deep molecular analyses have divided non-GCIMP GBMs into
unknown. Here we combined computational and mathematic
found that these tumors appear to be initiated by broad genom
and PTEN loss and evolve from a common glioma precursor
secondary molecular subtype characteristics by EGFR and P
evolution. Our findings provide insights into the natural histo
events.
288 Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc.ciated with canonical mutations such as PDGFRA amplification
in PN GBM, loss of NF1 in MES GBM, and amplification of
EGFR in CL GBM. In the case of NL GBMs, particular molecular
abnormalities remain unidentified.
One of the best-studied GBM subclasses is PN GBM, some
of which carrying mutant IDH1 or IDH2 and have the
methylator phenotype denoted by glioma-CpG island methyl-
ator phenotype (GCIMP) (Noushmehr et al., 2010). Although
the transcriptomal patterns for GCIMP tumors resemble those
of the other PN GBMs (non-GCIMP), their biology is sig-
nificantly different in that the GCIMP GBMs display global hy-
permethylation of CpG islands, characteristic copy numberfour classes, but the relationship between these subtypes is
al analyses of human GBM data with mouse modeling and
ic alterations driven partly by increased PDGFA expression
that is lethal and proneural in character. The acquisition of
DGFRA amplification or NF1 loss is achieved late in GBM
ry of GBMs and therapeutic strategies targeting these late
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Non-GCIMP GBM Evolves from a Common PN Precursoralterations, and prolonged patient survival, suggesting that
these tumors represent high-grade versions of grade 2 and 3
diffuse gliomas, which are commonly GCIMP and, thus, repre-
sent secondary GBMs (Noushmehr et al., 2010; Ohgaki and
Kleihues, 2013).
The existence of different GBM subtypes raises questions
regarding their natural history and the temporal sequence in
which individual alterations arise (Bhat et al., 2013; Phillips
et al., 2006; Sottoriva et al., 2013). Furthermore, it is unclear
whether these subgroups are fundamentally different tumors
from their inception or whether they evolve from a common gli-
oma precursor. Given the evidence of spontaneous conversion
of human PN to MES tumors and observed subtype mosaicism
within the same tumor (Phillips et al., 2006; Sottoriva et al.,
2013), the GBM subtypes might be directionally variable from
one subtype to another. Finally, it remains unclear whether the
existence of subgroups has therapeutic implications (Bhat
et al., 2013). For example, the subtype-defining mutations may
be promising therapeutic targets if they represent initiating ge-
netic events in glioma evolution, but their inhibition would likely
not provide a lasting therapeutic benefit if they represent late
events.
Chromosome instability is common in human cancers. It is
characterized by widespread chromosome (chr) copy number
changes, such as gain or loss of whole chr or fractions thereof
(Lengauer et al., 1998). Gain of chr7 as well as loss of chr10
and parts of chr9 are very frequent in gliomas. Alteration of
chr7 frequently includes focal amplification of the EGFR locus
(The Cancer Genome Atlas Research Network, 2008). Neverthe-
less, forced expression of the wild-type epidermal growth factor
receptor (EGFR) or the constitutively active EGFRvIII mutant
alone does not form gliomas in mice (Holland et al., 1998; Zhu
et al., 2009), suggesting that EGFR might not be an initiator of
this tumor type.
Genome-wide high throughput sequencing efforts have led to
the identification of many genomic alterations in cancer ge-
nomes, but it remains a challenge to identify genuine driver
genes from the many genes located within a large chromosomal
event. Here we utilized a combined computational and experi-
mental approach to investigate the natural history of human
non-GCIMP GBMs.
RESULTS
We first utilized genomic data from The Cancer Genome Atlas
(TCGA) to investigate the frequencies and types of genomic
alterations in GBM (The Cancer Genome Atlas Research
Network, 2008). The overall pattern of broad gains and losses
in the GCIMP tumors showed some similarities to that in the
non-GCIMP PN GBM (Noushmehr et al., 2010) but were strik-
ingly similar between the non-GCIMP PN GBM and other non-
GCIMP subtypes (Figure 1A; Table S1 available online). These
patterns suggest that all non-GCIMP GBMs are very similar
with respect to genomic alterations acquired during their evolu-
tion and distinct from the GCIMP tumors. We then performed a
phylogenetic analysis of copy number, mRNA expression, so-
matic mutations, and promoter methylation data of the non-
GCIMP subgroups and found that PN GBMs located separately
on the phylogenetic trees generated by each of these data types,suggesting that they are distinct from other non-GCIMP sub-
types (Figure 1B).
Gain of several copies of chr7 and loss of one copy of
chr10 were the most frequent events in non-GCIMP GBMs,
with frequencies of 86% and 90%, respectively (Figures 1A
and 1C). GCIMP tumors almost never lose the entire chr10
but show similar frequencies of loss (26%) and amplification
(24%) of 10p (Figures 1A and 1C). Note that gain of chr7
refers to the gain of a few copies of the whole chr7, which is
different from amplification of any specific gene on chr7,
and loss of chr10 refers to the loss of a whole copy of chr10
but leaving the other copy intact, which is not synonymous
with focal deletion of any gene on chr10. These events are
distinct from the commonly reported high-level amplification
and deletion of specific genes in GBMs, such as PDGFRA,
EGFR, or MET (The Cancer Genome Atlas Research Network,
2008).
When investigating 7p and 7q separately for all GBM sub-
types, we found that 7p gain ranged from 81% for PN GBMs
to 95% for MES GBMs, whereas 7q gain ranged from 79% for
PN GBMs to 93% for MES GBMs (Figure 1C). In general, 7p
and 7q gain were balanced (Figure 1D), with the exception of
GCIMP tumors, in which 7q gain occurred in 24% of tumors
and 7p gain in 15%. These data imply that, for non-GCIMP
GBMs, chr7 is gained as the entire chromosome. Balanced
chr7 gain is present in 82% of all non-GCIMP GBM samples
and represents the most common chromosomal abnormality in
these tumors. Non-GCIMP cases with a normal copy number
of both chr7 and chr10 were rare (2%) (Figure S1A; Tables S2
and S3) and had a similar age and survival distribution as GCIMP
tumors (Figures S1B and S1C), suggesting that some of these
non-GCIMP cases are potentially misclassified GCIMP tumors
(Figure S1D).
Mathematical Modeling Suggests Gain of Chr7 and Loss
of Chr10 as First Events in All Non-GCIMP
GBM Subtypes
The high prevalence and even distribution of chr7 gain and chr10
loss in all non-GCIMPGBMsubtypes raises the question of when
these events occur during GBM development. Therefore, we uti-
lized a computational methodology, Retracing Evolutionary
Steps in Cancer (RESIC), to determine the temporal sequence
of genetic alterations during tumorigenesis from cross-sectional
genomic data of a population of tumors at their fully transformed
stage (see also Supplemental Experimental Procedures) (Attolini
et al., 2010; Cheng et al., 2012). Applying RESIC to TCGA data
(The Cancer Genome Atlas Research Network, 2008) to examine
the temporal order of the known subtype-specific alterations
EGFR (CL GBM),NF1 (MESGBM), and PDGFRA (PN GBM) (Ver-
haak et al., 2010), together with gain of chr7 and loss of chr10, we
identified chr7 gain togetherwith chr10 loss as the first event in all
subtypes of GBM (Figure 2A; Figures S2A and S2B). Loss of
CDKN2A was another early event in all subtypes. Further ana-
lyses based on samples with mutational information only (n =
85 for non-GCIMP samples) revealed that TP53mutations arose
afterCDKN2A loss (Figure 2B; Figure S2C). Finally, when consid-
ering all frequent chromosome arm-level events, we found that
chr7 gain and chr10 loss arise before any other broad gains or
losses (Figure 2C; Figure S2D). An almost identical ordering ofCancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc. 289
Figure 1. Somatic Copy Number Alterations and Their Frequencies in GBM
(A) Genome plot visualizing frequencies of copy number gains (red) and losses (blue) along the genome in GCIMP tumors and the four non-GCIMP subtypes
(proneural, neural, mesenchymal, and classical GBM).
(B) Phylogenetic analysis in all GBM samples determining the putative evolutional order in GBM subtypes using all data types (copy number, mRNA expression,
somatic mutation, and methylation) and the Neighbor Joining algorithm. Artificial samples with exactly two copies in the whole genome serve as a normal copy
number control. For the DNA methylation analysis, the HM27 and HM450 platforms are shown.
(C) Histograms showing the frequencies of whole arm gains and losses of both chr7 and chr10 in each subtype separately. Homozyg., homozygous; Amp.,
amplification.
(D) Copy numbers of the p and q arms of chr7 and chr10 for all TCGA samples stratified by GBM subtype.
See also Figure S1 and Tables S1, S2, and S3.
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kel and Sullivant, 2009) (Figure S2E).
To delineate the clinical implications of these arm-level events,
we investigated the association between chr7 gain or chr10 loss
and GBM patient survival. Copy numbers of chr7 and chr10
correlate negatively and positively, respectively, with survival
(Figures 3A and 3B). This finding arises primarily because these
events do not occur as frequently in GCIMP tumors and because
patients with these tumors survive longer, on average, than
patients with non-GCIMP GBMs (Noushmehr et al., 2010). How-
ever, even in the non-GCIMP GBMs, chr7 gain correlates with
poor survival of patients, but only in the case of PN GBM (Fig-
ure 3A). These data suggest that a gene or several genes on
chr7 drive the gain of copy number early in GBM evolution and
promote the aggressive character in PN GBM. By contrast, the
lack of association of chr10 loss with overall survival might be
due to haplosufficiency of genes on chr10 (Figure 3B).290 Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc.Computational Analysis Suggests PDGFA and PTEN as
Major Drivers of Nondisjunction Events
We aimed to identify the genes on chr7 and chr10 that drive the
acquisition of these arm-level events, lead to the poor survival of
patients, and are potential targets for therapies. We designed a
computational algorithm consisting of two steps. The first step
ranks genes based on the extent of correlation between their
copy number and expression levels. Genes are first sorted by
the fold change of expression between tumors that do and
do not harbor the arm-level event. Genes with anticorrelation
of copy number and mRNA levels are excluded. In the second
step, the resulting gene list is filtered further by the degree of
correlation between a gene’s expression level and patient
survival.
When applying the first step to genes on chr7 for all non-
GCIMPGBM samples, we identified a set of genes with the high-
est expression response to increased copy number predicted to
A B C Figure 2. Temporal Sequence of Events in
Glioma Development
(A) Order of events for subtype-specific copy
number alterations per subtype.
(B) Order of events for all GBM samples for which
TP53 point mutation data was available (n = 85).
(C) Order of chromosome level copy number
alterations. Black ovals represent distinct muta-
tional events. Arrows represent an ordering of
events detected by RESIC. Rectangles containing
events represent sets of eventswhereRESICcould
not distinguish an order of events. Black denotes
orderings that are shared across subtypes. Red,
yellow, green and blue denotes classical, mesen-
chymal, neural, and proneural subtype-specific
orderings, respectively. Orderings shared by mul-
tiple subtypes, but not all subtypes, are denoted by
multicolored arrows and rectangles.
See also Figure S2.
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selected in this first filtering because a low-level gain of EGFR,
as foundwith whole chr7 gain, is not correlated with its increased
expression (p = 0.19, Student’s t test, EGFR normal versus gain,
Figure S3A). High-level amplification of EGFR is predicted by
RESIC to be a late event (Figure 2A), and such focal amplification
of EGFR correlates significantly with its expression level (p <
0.001, Student’s t test, EGFR gain versus focal amplification,
Figure S3A). Almost all identified point mutations in EGFR as
well as in EGFRvIII were found in samples with high-level focal
gene amplification (Figure S3A; Table S1). These data further
support the hypothesis that EGFR may not be a driver of initial
oncogenic events in this tumor type but, rather, contributes to
tumor progression or maintenance through high expression
driven by focal amplification arising at later stages of tumor
formation.
The second step then showed that a direct correlation be-
tween expression levels and survival was uninformative because
many genes on chr7 displayed a correlation between their copy
number and expression. Thus, their expression also correlates
with survival in PN GBM (Table S4). Therefore, we investigated
the correlation between survival and the expression levels of
pathways downstream of genes on chr7. When applying this fil-
ter to chr7, we found that, of the 190 genes whose expression
fold change between cases of normal and gained chr7 copy
number was at least 1.25, 13 genes displayed a correlation
with survival in PN GBMs of p < 0.05 (Table S5). Figure 3C sum-
marizes the two filters applied to chr7. This combined ranking
approach identified PDGFA as the highest-ranking gene on
chr7 (Figure S3B; Tables S5 and S6), i.e., expression of PDGFA
downstream genes was associated with overall survival, and
chr7 gain increased PDGFA mRNA levels significantly. There-
fore, PDGFA most likely is the gene providing the strongest se-
lective advantage to gaining extra copies of chr7.
We then sought to identify potential drivers of chr10 loss.
The application of the two steps outlined above is only appro-
priate for chromosomal gains because the correlation between
expression levels and patient outcomes necessitates a degree
of variability in copy number across patients. Chr7 gain meets
this requirement because patients may harbor three, four, ormore copies of chr7. By contrast, chr10 loss results in a single
remaining copy of chr10 in almost all cases (Figures 1C and 1D),
therefore necessitating an alternative strategy. Because loss of
chr10 and gain of chr7 almost always co-occur (p = 0.001,
Fisher’s exact test, Figures 1A and 1C), we hypothesized that
the phenotypic effect of a main driver of chr10 loss might
amplify the effects of the driver of chr7 gain and vice versa,
therefore likely activating the same pathways and resultant
changes in gene expression. We also ranked the genes on
chr10 by the association of the expression levels of their down-
stream genes with survival (Tables S4 and S5). The tumor sup-
pressor PTEN displayed a highly significant survival association
between the expression levels of its downstream genes and
survival (false discovery rate [FDR] < 0.02) (Figure 3D; Fig-
ure S3C; Table S5) and also a large overlap of downstream
genes of PDGFA (Figure 3E), suggesting that it may be a signif-
icant driver of chr10 loss in these tumors. In non-GCIMP GBM
subtypes other than PN GBMs, we did not identify any such
strong pathway enrichments of chr7 and chr10, consistent
with the lack of correlation of chr7 gain with survival in these
GBM subtypes (Figure 3A). Our computational approach there-
fore suggests PDGFA and PTEN as primary drivers of the chr7
and chr10 nondisjunction events, respectively. Note that this
analysis does not suggest that these genes alone are sufficient
for driving these events.
Mouse Modeling Suggests that the Predicted First
Events in Glioma Evolution Are Sufficient to
Induce Gliomagenesis
Our computational analyses predict that elevated expression
of PDGFA represents the strongest initial driving event in glioma
evolution. This is noteworthy because of the well described role
of PDGF signaling in GBM, especially in PN GBM (Brennan et al.,
2009; The Cancer Genome Atlas Research Network, 2008; Ver-
haak et al., 2010). Note that the elevated expression of PDGFA
as a likely driver is not the same as the frequently reported
high-level focal amplification of PDGFRA found primarily in PN
GBM. The PDGF signaling network is transmitted by four ligands
(A, B, C, and D isoforms) and two protein tyrosine kinase recep-
tors (a and b). Overexpression of PDGFB generates PDGFBCancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc. 291
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Figure 3. Drivers of Chr7 and Chr10 Alter-
ations in the Proneural Subtype
(A and B) Forest plots showing the hazard ratios
(HR, squares) of chr7 gain (A) and chr10 loss (B)
and their confidence intervals. HRs significantly
larger than 1 (A) or lower than 1 (B) signify a copy
number change associated with a poor prognosis.
The square size is proportional to the sample size.
(C and D) Genes on chr7 (C) and chr10 (D) ranked
by association of downstream genes with overall
survival, with the corresponding p values shown
on the y axis. Genes were considered with a fold
change (x axis) in expression of larger than 1.25
(averaged over both Affymetrix and Agilent plat-
forms) when comparing patients with normal and
altered chr7 and chr10 copy numbers. The top-
ranking hits are shown in blue.
(E) The overlap in downstream genes of PDGFA in
the Kyoto Encyclopedia of Genes and Genomes
pathway database with the top-ranking genes on
chr10 (x axis).
See also Figure S3 and Tables S4, S5, and S6.
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Non-GCIMP GBM Evolves from a Common PN Precursorhomodimers (BB dimers) that activate both PDGFRa and b,
whereas overexpression of PDGFA only activates PDGFRa (An-
drae et al., 2008; Heldin and Westermark, 1999). In animal
modeling systems, signaling driven by PDGFB alone is sufficient
to form GBMs, and additional loss of Tp53, Cdkn2a (Ink4a-Arf),
or Pten accelerates tumor formation (Dai et al., 2001; Fom-
chenko et al., 2011; Hu et al., 2005; Shih et al., 2004; Squatrito
et al., 2010). Although the PDGFB protein level is elevated in
many PN GBMs, it does not correlate with the PDGFB mRNA
level in these tumors (Brennan et al., 2009). Moreover, the alter-
ation ofPDGFB is rare inGBMs (Verhaak et al., 2010), suggesting
that other PDGFs, such as PDGFA, could potentially drive onco-
genesis in this GBM subtype. However, it remains to be deter-
mined whether elevated PDGFA is sufficient to initiate gliomas,
either alone or in combination with other early events such as
CDKN2A, TP53, or PTEN loss (Figures 2A and 2B; Figures S3C
and S3D) (Jackson et al., 2006; Nazarenko et al., 2011).
Therefore, we tested the ability of genes predicted to drive hu-
man GBM evolution to induce gliomas in vivo using the replica-
tion-competent avian sarcoma-leukosis virus long terminal
repeat with splice acceptor/tumor virus a (RCAS/tv-a) system
that allows postnatal cell type-specific gene transfer (Holland
et al., 1998; Holland and Varmus, 1998). To determine whether
PDGFA alone is sufficient for glioma formation, we infected
neonatal N/tv-a mice (Nestin-expressing cell of origin, n = 11)
and G/tv-a mice (GFAP-expressing cell of origin, n = 14) with
an RCAS retroviral vector expressing human PDGFA (RCAS-
PDGFA) (Figures S4A and S4B). All N/tv-a mice were sacrificed
at 4 months of age, when the first mice developed symptoms
of intracranial pathology. Eight of eleven mice harbored brain
tumors of various sizes demonstrating histological features of
grade 2 human oligodendrogliomas, including round nuclei, peri-
nuclear halos, and strong Olig2 and lower GFAP expression (Fig-292 Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc.ure 4A and data not shown). All G/tv-a
mice formed tumors ranging from 159–
323 days postinjection. Many developed
high-grade gliomas with histologic fea-tures of human oligodendroglioma (Figure 4B; Figure S4C).
These data indicate that elevated PDGFA expression is sufficient
to initiate gliomagenesis in vivo.
Pten Loss Shortens Survival of Mice with PDGFA-
Induced Gliomas but Is Not Sufficient to Induce
Gliomas Alone
RESIC analysis predicted that combined loss of chr10 and gain
of chr7 are the earliest events in non-GCIMP GBM subtypes.
Previous results using the RCAS/tv-a system have shown that
loss of Pten alone is insufficient for glioma formation in mice
(Hu et al., 2005), suggesting that loss of Pten might play a
supportive role in PDGFA-responsive cells rather than serving
as the tumor initiator. To confirm the supportive role of Pten
loss in this context, we created an RCAS vector expressing
mRFP and a short hairpin designed to knock down Pten expres-
sion (RCAS-shPten) (Figures S4A, S4D, and S4E). Infection of
both wild-type N/tv-a (n = 3) and G/tv-a (n = 11) mice with this
vector alone did not result in brain tumors by approximately
4months of age. However, consistent with the RESIC prediction,
simultaneous Pten loss significantly shortened the survival of
mice with PDGFA-induced gliomas and elevated the grade of
the tumors (Figures 4A and 4B; Figures S4F–S4H). These fea-
tures were also observed in a cre-mediated Pten deletion model
(Figure 4B; Figure S4F).
PDGFA-Induced Tumors Resemble PN GBMs, but
PDGFB-Induced Tumors Display a More MES
GBM-like Character
RESIC analysis also predicted that loss of CDKN2A occurs after
gain of chr7 (elevation of PDGFA expression) in these tumors.
Therefore, we injected neonatal N/tv-a;Cdkn2a(Ink4a-Arf)/
mice with RCAS-PDGFA (n = 25) (Figure 4C). Tumors occurred
E 
F 
A B
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C   
Figure 4. PDGFA Induces Gliomas with Similar Expression Patterns as Human Proneural GBMs in Mice
(A–C) Kaplan-Meier survival curves showing symptom-free survival of PDGFA- or PDGFB-induced gliomas in Nestin (N)/tv-a (A), GFAP (G)/tv-a, orG/tv-a;Ptenfl/fl
(B) and N/tv-a;Cdkn2a/;Ptenfl/fl mice (C). Tumors were generated by the injection of the indicated RCAS virus into neonatal brains. *p < 0.05, **p < 0.005,
***p < 0.001, ****p < 0.0001. ns, not significant; ND, not determined.
(D) Representative H&E and immunohistochemical analysis of the PDGFA- and PDGFB-induced gliomas in N/tv-a;Cdkn2a/;Ptenfl/fl mice. Boxes denote the
enlarged region. Scale bars, 100 mm.
(E) GSEA of the RCAS-PDGFA- and RCAS-PDGFB-induced gliomas in N/tv-a;Cdkn2a/;Ptenfl/fl mice. Gene expression profiles were compared between the
PDGFA-induced (n = 7) and PDGFB-induced (n = 5) gliomas based on the TCGA subtype signatures (Verhaak et al., 2010). Bar plots visualize enrichment p values
(y axis) of the four subtype signatures in the ranking of genes by differential expression (PDGFA versus PDGFB). A low p value indicates consistent expressionwith
the subtype, i.e., many genes known to be upregulated in the subtype are up, and downregulated genes are down.
(F) GSEA of the RCAS-PDGFA/shp53- and RCAS-shNf1/shp53-induced gliomas in N/tv-a and G/tv-a mice.
See also Figure S4 and Table S7.
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Non-GCIMP GBM Evolves from a Common PN Precursorin these mice with 100% penetrance and a median survival of
65 days. These tumors demonstrated histological features of
human oligodendroglioma and displayed a high-grade histology
with uniformly abundant pseudopalisading necrosis, hypervas-
cularity, and brisk microvascular formation throughout the tumor
(Figures 4C and 4D; Figure S4I). Interestingly, additional loss of
Pten in a Cdkn2a/ background did not shorten tumor latency
further (Figure 4C).
We then compared gliomas induced by PDGFA and PDGFB
in newborn and adult N/tv-a;Cdkn2a/ mice. We found thatPDGFA generated tumors with a longer latency than PDGFB
and that gliomas induced by either ligand arose in newborn
mice faster than in adults (Figure 4C; Figure S4J) (Squatrito
et al., 2010). The histology of tumors induced by PDGFA and
PDGFB was generally similar. However, the vasculature and
stroma were notably different (Figure 4D; Figure S4K). PDGFB-
induced gliomas showed a spindled vasculature and atypical
stroma (PDGFB activates both a receptors in the tumor cells as
well as b receptors in the perivascular stroma), whereas tumors
generated by PDGFA (which activates only the a receptor)Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc. 293
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Non-GCIMP GBM Evolves from a Common PN Precursorshowed glomeruloid microvascular proliferation more similar to
that seen in human GBM (Figure 4D; Figure S4K) (Helmy et al.,
2012; Hermansson et al., 1988).
Subsequently, we profiled these tumors by gene expression
analysis to determine which human GBM subtype they resem-
bled most closely and found that PDGFA-induced gliomas
in the mouse more closely resembled PN GBMs in humans,
whereas the PDGFB-induced tumors shifted toward MES
GBMs (Figure 4E). The Olig2-expressing tumor cells from
PDGFB-induced gliomas, which constitute the bulk of the tumor
(Figure 4D), show a strongly proneural expression profile
(Dougherty et al., 2012). Therefore, the MES character of the
PDGFB-induced gliomas possibly reflects the abundant atypical
perivascular stroma and other nontumor stromal cell types found
in these tumors (Figures 4D and 4E; Figure S4K).
Loss of TP53 as well as PTEN or CDKN2A in
PDGFA-Induced Gliomas Results in a Highly Lethal
Disease in Mice
CDKN2A loss occurs frequently in human PN GBMs, but
this GBM subgroup also commonly harbors mutations in TP53
(Verhaak et al., 2010). Therefore, we determined whether loss
of Tp53 would cooperate with PDGFA-induced gliomas in a
similar way as Cdkn2a loss. We generated an RCAS vector
expressing both mRFP and a short hairpin designed to knock
down Tp53 expression (RCAS-shp53) (Figures S4A and S4L–
S4P). Infecting mice with this vector alone did not generate
gliomas by approximately 1 year of age. However, when com-
bined with RCAS-PDGFA, high-grade gliomas formed in 100%
of mice with a median survival of 69.5 days in wild-type N/tv-a
mice (n = 18) and 56 days in wild-typeG/tv-amice (n = 31), similar
to PDGFA in a Cdkn2a/ background (Figures 4A4C). The
tumors demonstrated histological features of human oligoden-
droglioma and displayed a high-grade histology similar to
PDGFA-induced tumors with Cdkn2a loss (Figure S4Q). Further-
more, the gene expression profiles of the gliomas induced by
PDGFA with loss of Tp53 showed a significant enrichment of
PN GBM genes (Figure 4F) as well as downstream orthologs of
human PDGFA identified in the abovementioned computational
analysis (Figure 3C; Figure S4R; Table S6). These observations
suggest that loss of the tumor suppressor genes PTEN,
CDKN2A, or TP53 is sufficient to enhance PDGFA-induced gli-
omas, resulting in highly lethal gliomas.
Simultaneous Loss ofNf1 and Tp53 InducesMESGBM in
the RCAS/tv-a Model
RESIC analysis predicts that the same early events in PN GBM
also occur in MES GBM but that NF1 loss occurs late in the
evolution of these tumors. In MES GBMs (as well as all non-
GCIMP GBMs), NF1 loss is associated with TP53 mutations
and, less commonly, with CDKN2A loss (Figure S5A) (Verhaak
et al., 2010). Furthermore, published mouse GBMmodels result-
ing from germline homozygous deletions ofNf1 and Tp53 show a
median survival of approximately 150–200 days (Reilly et al.,
2000; Zhu et al., 2005), but they do not recapitulate a human
MES GBM expression pattern (Liu et al., 2011). Other groups
recently generated an H-RasV12-shp53 glioma model
mimicking Nf1;Tp53 loss and reported H-RasV12-shp53-driven
GBMs to show MES gene expression (Friedmann-Morvinski294 Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc.et al., 2012). However, there is no mouse model with Nf1;Tp53
loss reported to create a GBM with MES gene expression.
More importantly, all of these GBM models were generated
using technologies different from what we used, making it diffi-
cult to compare them. Therefore, to allow direct comparison of
our PDGFA models and mouse models of MES GBM, we engi-
neered the RCAS/tv-a system to generate MES GBM from
normal cells. We then set out to initially reproduce the published
effect of combined loss of Nf1 and Tp53.
We created an RCAS vector expressing GFP and a short
hairpin designed to knock down Nf1 expression (RCAS-shNf1)
(Figures S4A, S4L, S4N, S4O, S5B, and S5C). Infection of both
wild-type N/tv-a (n = 20) and G/tv-a (n = 12) mice with this vector
alone did not generate tumors by approximately 1 year of age.
However, infection with the combination of RCAS-shNf1 and
RCAS-shp53 led to the formation of gliomas in 100% of mice,
with a median survival of 146 days for G/tv-a (n = 52) and
221 days for N/tv-a (n = 32) mice (Figures 5A and 5B; Figures
S4O and S5D–S5G). These latencies are similar to those pub-
lished for gliomas formed by germline models of combined Nf1
and p53 loss (Reilly et al., 2000; Zhu et al., 2005). Histologic
analysis of theG/tv-aandN/tv-a tumors showedstronger expres-
sion of theMESmarkers vimentin andCD44, and theMESmaster
regulatorspSTAT3andC/EBPb in theG/tv-a tumors than in theN/
tv-a tumors (Figure 5B and data not shown) (Carro et al., 2010).
Gene expression profiling of these tumors (G/tv-a, n = 7; N/tv-a,
n = 11) demonstrated that they were more MES-like than those
driven by PDGFA (Figure 4F) and that gliomas arising in G/tv-a
mice had a more MES-like expression pattern than those arising
inN/tv-amice (Figure 5C). Collectively, these data suggest that it
is possible to generate MES gliomas from normal cells in post-
natal micewith a similar latency to that seen with germline strate-
gies that delete both genes (Reilly et al., 2000; Zhu et al., 2005).
While Nf1 loss in N/tv-a;Cdkn2a/;Ptenfl/fl mice was consider-
ably less efficient than loss of Tp53 for the formation of gliomas,
as supported by the fact that NF1 loss is associated with TP53
mutations and, less commonly, CDKN2A loss (Figures S5A and
S5E; Table S7) (Verhaak et al., 2010).
Additional Loss of NF1 Converts the PDGFA-Induced PN
Phenotype to a MES Gene Expression Pattern
The tumor latency for PDGFA-induced gliomas versus those
induced by Nf1 loss is striking. In the mouse model, the loss of
both Nf1 and Tp53 occurs simultaneously, whereas in humans,
there would be multiple separate mutational events in a normal
cell that would lead to loss of function of both alleles of NF1
and mutation of TP53. Such an evolutionary pathway to MES
GBMs formation, although possible, might be much slower
than that for PN GBMs, which requires elevated expression
from a single gene, such as PDGFA. Moreover, the importance
of the chronological order of mutations in MES glioma formation
is underscored by the fact that, in mice, loss of Nf1 is less effi-
cient at enhancing gliomas than loss of Tp53 in the context of
forced PDGFA expression (Figure 4B). Finally, global copy num-
ber and RESIC analysis predicts that MES GBMs initially arise
from tumors with the same alterations as PN GBMs and that
they lose NF1 later (Figure 2).
Therefore, we sought to determine whether NF1 loss in PN-
GBM could induce a PN-to-MES GBM transition. We obtained
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Figure 5. Simultaneous Loss of Nf1 and Tp53 Induces MES Gliomas in the RCAS/tv-a Model
(A) Kaplan-Meier survival curves showing symptom-free survival and relative tumor grade of the RCAS-shNf1/shp53-induced gliomas in N/tv-a and G/tv-amice.
The percentage of tumors exhibiting WHO grade II (G2), III (G3), and IV (GBM) histological features are shown for each genotype.
(B) Representative H&E and immunohistochemical analysis for the indicated protein of the RCAS-shNf1/shp53-induced glioma in G/tv-amice. The box denotes
the enlarged region. Scale bars, 100 mm.
(C) GSEA of the RCAS-shNf1/shp53-induced gliomas in G/tv-a and N/tv-a mice.
See also Figure S5.
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Non-GCIMP GBM Evolves from a Common PN Precursortwo PN GBM cell lines that contain an amplification of PDGFRA,
and, by expression profiling, fit the criteria for the PN subtype
(Figures 6A and 6B; Figures S6A and S6B) (Ozawa et al., 2010).
Expression profiling of the lines before and afterNF1 knockdown
showed that the original PN expression pattern was shifted
toward a MES or CL pattern in both cases (Figure 6B; Figures
S6B and S6C). Moreover, knockdown of Tp53 or Nf1 alone was
sufficient to induce PN and MES gene enrichment in murine
neurosphere culture, respectively (Figure 6C; Figure S6D). These
results suggest that NF1 function regulates transcriptional
pathways necessary for mesenchymal conversion. To examine
whether NF1 directly regulates the expression of mesenchymal
transcriptional factors (TFs), we performed a TF enrichment anal-
ysis in murine neurosphere (Figure S6E), murine glioma (Fig-
ure S6F), and TCGA (Figure S6G) data sets. We identified 14 TF
gene sets (MSigDB 4.0) corresponding to 9 different TFs, that
were significantly (FDR < 0.05) associated with NF1 loss in the
three data sets (Figure 6D; Figures S6E–S6G). Some of these14 TF gene sets associated with NF1 loss presented a high sim-
ilarity to eachother (Figure 6D) anddisplayeda significant overlap
with recently reportedmesenchymal TF target genes (Carro et al.,
2010) (Figure 6E). Notably,NF1 loss was associated significantly
with two main mesenchymal TFs, C/EBPb and RUNX1 (Fig-
ure 6F). By contrast, perturbations of STAT3 andC/EBPb expres-
sion did not affect NF1 expression in human GBM cells and
mouse stem cells (Figures S6H and S6I), implying that these
MES-associated TFs are downstream of NF1 loss. ShNf1-
induced tumors showed a statistically significant association be-
tween loss of NF1 and gene expression changes related to the
mammalian target of rapamycin (mTOR) pathway (Figure S6J).
Furthermore, loss of NF1 did not appreciably elevate Erk or Akt
phosphorylation (p) but did elevate pS6RP, suggesting that NF1
loss may affect mTOR activity in an Akt-independent manner
(Figure 6A). Therefore, we treated the two NF1 knockdown cell
lines with the mTOR inhibitor rapamycin (Figure S6K) and
observed a marked but variable shift from MES/CL toward PNCancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc. 295
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Figure 6. Additional NF1 Loss Induces Proneural-to-Mesenchymal Conversion In Vitro and In Vivo
(A) Western blot analysis of two humanGBM cell lines (TS543 and TS667) expressing control shRNA (Ctrl-sh) or NF1 shRNAs (target sequence #2 and #5) with the
indicated antibodies.
(B) GSEA of humanGBMcell lines. Gene expression profiles were compared between untreated cells, 0.1%DMSO- or 1nM rapamycin-treated cells for 5 hr in two
different cell lines (TS543 and TS667) expressing control or NF1 shRNA. Each sample was analyzed in triplicate. Control shRNA samples of the TS543 and TS667
cells also have technical duplicate samples.
(C) GSEA of murine neurosphere lines. The gene expression profiles were analyzed in betweenN/tv-a neurosphere lines expressing RCAS-shGL2, RCAS-shNf1,
RCAS-shp53, or RCAS-shNf1/shp53. The subtype gene signature enrichment was determined by comparing the control shRNA sample (shGL2) with each
shRNA sample. Each sample was analyzed in triplicate.
(D) The overlap index of the 14 significant gene sets corresponding to 9 different TFs. High overlaps are shown in dark blue.
(E) Cytoscape visualization of the overlap of the 14 significant TF gene sets and the GBM mesenchymal gene signature (Carro et al., 2010). Diamond-shaped
nodes represent the 14 TF gene sets. Circular nodes represent TF target genes in both the mesenchymal gene signature and the 14 TF gene sets. TFs and target
genes are connected by blue edges. The p value for the overlap of the mesenchymal gene signature and the 14 TFs was 0.005 (hypergeometric distribution).
(F) Correlation of MES-TF expression with NF1 expression in the TCGA Agilent data. p values for anticorrelation with NF1 expression were less than 0.001 for
C/EBPb, RUNX1, STAT5A, STAT6, and IRF1.
See also Figure S6.
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Non-GCIMP GBM Evolves from a Common PN Precursorexpression, suggesting that blockade of mTOR rescues the
effect of NF1 loss in PN GBM lines (Figure 6B).
Finally, we determined whether NF1 loss could convert PN
GBMs to MES GBMs in mice. To test sequential loss, we initially
generated PDGFA/shp53 tumors by concurrent stereotactic in-
jection of the two vectors and then secondary infection with296 Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc.the GFP-shNf1 vector into the tumors using the same stereotac-
tic coordinates 2–4weeks later. The RCAS-GFP-shNf1 virus was
incorporated regionally in 15 of 20 mouse gliomas (Table S7).
Many of the GFP-positive regions were detected in low PDGFA
expression areas and/or the tumor periphery. Higher expression
for MES-related markers, such as CD44, pSTAT3, and C/EBPb,
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Figure 7. Additional Nf1 Loss Induces Proneural-to-Mesenchymal Conversion In Vivo
(A) Representative H&E and immunohistochemical analysis for the indicated protein of the RCAS-PDGFA/shp53-induced glioma secondarily incorporating the
RCAS-GFP-shNf1 virus in G/tv-a mice. Circles 1 and 2 represent mesenchymal and proneural tumor lesions, respectively. Scale bars, 100 mm.
(B) Kaplan-Meier survival curves showing symptom-free survival of PDGFA/shp53- or PDGFA/shp53/shNf1-induced gliomas inN/tv-a (left panel) andG/tv-a (right
panel) mice. Tumors were generated by simultaneous injection of the relevant RCAS virus into neonatal pup brains. Survival curves of the RCAS-PDGFA/shp53-
induced tumors from Figures 4A and 4B are also shown for comparison. ***p = 0.0004, ****p < 0.0001.
(C) GSEA of the RCAS-PDGFA/shp53- and RCAS-PDGFA/shp53/shNf1-induced gliomas in N/tv-a and G/tv-a mice.
Cancer Cell
Non-GCIMP GBM Evolves from a Common PN Precursorwas associated preferably with GFP-positive regions (i.e., NF1
knockdown) and/or adjacent areas (Figure 7A). For simultaneous
loss of NF1, we compared the GBMs generated by the double
combination of RCAS-PDGFA and RCAS-shp53 (G/tv-a, n =
31; N/tv-a, n = 18; see above) to the triple combination of
RCAS-PDGFA, RCAS-shp53, and RCAS-shNf1 (G/tv-a, n =
26,;N/tv-a, n = 18). The additional loss ofNf1 in the triply infected
mice resulted in gliomas occurring significantly faster than the
doubly infected mice, both from the G/tv-a (Figure 7B, right
panel) and the N/tv-a (Figure 7B, left panel) cell of origin. The
expression patterns for the two populations showed that the
doubly infected mice generated gliomas with a PN gene expres-
sion pattern (Figures 4F and 7C), whereas the gliomas from the
triply infected mice shifted toward MES (Figure 7C).
DISCUSSION
There has been much discussion about the implications of the
molecular subgroups of GBM. The data presented here connect
the GBM subtypes in an evolutionary framework where the pri-
mordial tumors are PN in character, with the other subgroups
evolving from them. Amplification of PDGFRA occurs primarily
in tumors that remain PN. Mathematical modeling suggests
that chr7 gain and chr10 loss are very common early geneticevents in all subtypes of non-GCIMP GBM. Further, we found
that the selective advantage for additional copies of chr7 is pri-
marily, but potentially not exclusively, driven by elevated expres-
sion of PDGFA and that a primary driver for loss of chr10 is
reduced expression of PTEN. These predictions were supported
by mouse modeling data indicating that overexpression of
PDGFA was sufficient to induce gliomas that were enhanced
by PTEN loss to give rise to GBM with a PN character. Note
that chr7 encodes many other genes with elevated copy number
by the gain of chr7, which may contribute to oncogenesis and
therapeutic resistance. Similarly, there could be genes on
chr10 additional to PTEN whose loss enhances oncogenesis or
alters the therapeutic response early in GBM evolution.
Loss of chr10, which occurs in nearly all non-GCIMP GBMs, is
represented by one copy loss. Therefore, it is intriguing to know
whether loss of function of the remaining allele is essential in
non-GCIMP GBM formation. A nonsilent somatic point mutation
in the remaining PTEN allele is found in 37.9% of all cases with a
single copy of chr10, and homozygous deletion was identified in
10% of non-GCIMP GBMs. Given that PTEN expression is also
regulated by promotermethylation andmicroRNA, the remaining
PTEN allele might be also inactivated by alternative mechanisms
in non-GCIMP GBMs (Baeza et al., 2003; Huse et al., 2009;
Wiencke et al., 2007). Furthermore, the level of PTEN mRNACancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc. 297
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Non-GCIMP GBM Evolves from a Common PN Precursorexpression decreased from diploid to hemi- and homozygous
loss in non-GCIMP GBMs. In mice, heterozygous loss of Pten
was sufficient to induce gliomas in combination with Tp53 loss,
with or without Nf1 loss, and the homozygous loss increased
the aggressiveness of tumors (Kwon et al., 2008; Zheng et al.,
2008). Therefore, heterozygous loss of PTEN appears to be
enough for initiating an abrogation of gene function in GBM
patients.
Mouse models can demonstrate that specific cell types, gene
combinations, and sequences of events are sufficient to form tu-
mors, but they alone do not prove that human tumors form that
way. The mathematical analysis of human GBM data presented
here indicates that a specific set and order of gene abnormalities
represent the major evolutionary pathway toward non-GCIMP
GBM. The mouse modeling shows that this specific predicted
series of events is sufficient to form PN-like GBM in mice and
that this character can be shifted to a MES one with subsequent
loss of Nf1, predicted to be a late event in the evolution of MES
GBM in humans. Further, given the highly similar copy number
patterns for most non-GCIMP GBM subtypes, it is likely that
most non-GCIMP GBM subtypes arise similarly.
Our studies suggest that cells harboring both chr7 gain and
chr10 loss are themost likely cells of origin for gliomas. However,
given the existence of a few cases of GBM in the TCGA data set
without copy number alterations of both chromosomes, there
clearly are exceptions. Indeed, as shown by our Nf1/Tp53 loss
model, it is possible that MES GBMs could arise de novo via a
different cell of origin and evolutionary pathway. Furthermore,
the relatively rare patients without chr10 loss have significantly
more whole chromosome 12 gains (FDR < 0.01), and patients
without chr7 gain have significantly higher odds of a PDGFRA
somatic mutation (p = 0.05, Fisher’s exact test). This might
also indicate that pathways affected by chr7 gain and chr10
loss can be interrupted with similar consequences by alterations
on other chromosomes. Nonetheless, the majority of non-
GCIMP GBMs are abnormal for chr7 and chr10 and most likely
arise from a PN-like precursor lesion.
This series of molecular events early in the development of
GBM is different from that seen in other cancer types induced
by point mutations or translocations with the generation of a sin-
gle oncogene in an otherwise normal background, such as
chronicmyeloid leukemia (Hehlmannet al., 2007). Theacquisition
of multiple pro-oncogenic alterations by copy number gain and
loss at the outset of tumor formation would reduce the likelihood
of success for targeted therapy against any specific signaling tar-
gets, especially those acquired late in the tumor’s evolution. The
data argue that PDGFA is the gene on chr7 that most likely pro-
vides the strongest selection for initial gain of chr7 at the begin-
ning of non-GCIMP GBM formation. However, other genes on
chr7, such as CUL1, CBLL1, ASNS, ARPC1A, and GLI3, might
have similar but less robust effects and could collectively trump
PDGFA expression later in GBM evolution. It remains to be eluci-
dated how our findings relate to other tumor types that also show
gains of large portions of chr7 and loss of chr10.
The chromosomal abnormalities early during GBM evolution
are interesting in light of the observation that aneuploidy for at
least one chromosome occurs in as many as 10% of all cells in
the normal adult brain (Iourov et al., 2006; Iourov et al., 2009)
and is even higher during development, reaching 30%–35%298 Cancer Cell 26, 288–300, August 11, 2014 ª2014 Elsevier Inc.(Bushman and Chun, 2013; Yurov et al., 2007). This higher prev-
alence in the brain compared with other organs has been sug-
gested to contribute to neuronal diversity (Bushman and Chun,
2013). However, from this diverse set of errors in chromosomal
number throughout the normal brain, only cells with loss of one
copy of chr10 and gain of variable numbers of chr7 give rise to
non-GCIMP GBMs. Given the prevalence of aneuploid cells in
the normal brain, it is likely that many cells with both gain of
chr7 and loss of chr10 exist in each individual. Therefore, other
mechanisms may contribute to the fact that GBMs are not
more prevalent. If aneuploidy in the CNS functions to generate
neuronal diversity, wemight speculate that the risk of developing
GBM may be the price paid for complex CNS function.
EXPERIMENTAL PROCEDURES
Data Sets of Human GBM Samples
We obtained segmented copy number data, raw and normalized mRNA
expression data, methylation data, and somatic mutation data from the
TCGA (The Cancer Genome Atlas Research Network, 2008). All analyses
were done in R/Bioconductor (Gentleman et al., 2004). The details of all
bioinformatic analyses are described in the Supplemental Experimental
Procedures.
Phylogenetic Analysis
To examine the relationship between GBM subgroups, we applied the
Neighbor-Joining algorithm (Saitou and Nei, 1987) independently to the
TCGA GBM Agilent expression, SNP copy number, promoter methylation,
and somatic mutation data, as described previously (Riester et al., 2010).
RESIC Analysis
To determine the temporal sequence of genetic alterations, two whole
chromosome events, chr7 non-disjunction and chr10 loss, as well as sub-
type-defining events (focal EGFR gain and amplification, PDGFRA gain and
amplification, and NF1 loss), we applied the RESIC algorithm to the GBM
data set, as described previously (Attolini et al., 2010; Cheng et al., 2012).
Pathway Analysis
To prioritize genes in large copy number alterations, we developed a compu-
tational method. The algorithm identifies genes fromdisease-related pathways
for which copy number gain has a profound impact on mRNA levels.
Transcription Factor Analysis
To examine whether NF1 loss had an impact on expression of certain TFs, a
gene set enrichment analysis (GSEA) was performed with MSigDB 4.0, which
provides 615 putative TF/target gene sets (c3 category) (Subramanian et al.,
2005).
Gene Expression Analysis for Murine Brain Tumors and
Neurosphere and Human GBM Cell Lines
Total RNAs were labeled by the Illumina protocol, followed by hybridization to
the BeadChip (Illumina). Raw data were processed at the Genomics Core
Laboratory of Memorial Sloan-Kettering Cancer Center (MSKCC) and then
normalized with the lumi R package (Du et al., 2008). For the GSEA, the Ver-
haak et al. subtype signatures were used (Verhaak et al., 2010).
Vector Constructs
The humanPDGFA cDNAwas purchased fromOriGene Technologies andwas
subcloned into the RCAS-Y vector (Dunn et al., 2000). For the generation of
the RCAS-shRNA vector, shRNAs were initially assembled in the pSUPER.re-
tro.puro vector (OligoEngine) or the pENTR-mRFP-H1 vector. The shRNAs
containing the H1 promoter were PCR-amplified and then inserted into the
RCAS-Y vector. For the pENTR-mRFP-H1 vector, LR recombination was
used to transfer the shRNAcontainingH1andmRFP into theRCAS-Destination
vector (Loftus et al., 2001) (see also Supplemental Experimental Procedures).
Cancer Cell
Non-GCIMP GBM Evolves from a Common PN PrecursorGeneration of Murine Brain Tumors
All animal experiments were done in accordance with protocols approved by
the Institutional Animal Care and Use Committees of MSKCC and Fred Hutch-
inson Cancer Research Center and followed NIH guidelines for animal welfare.
The RCAS/tv-a system used in this work has been described previously
(Holland et al., 1998, 2000; Holland and Varmus, 1998; Hu et al., 2005; Uhrbom
et al., 2004). GFAP (G)/tv-a, G/tv-a;Ptenfl/fl, G/tv-a+/;Tg-Ef luc, Nestin (N)/tv-a
(agouti), or N/tv-a;Cdkn2a(Ink4a-Arf)/;Ptenfl/flmice were used for the RCAS-
mediated gliomagenesis in this study. After injection of the relevant RCASvirus,
micewereobserveduntil theydevelopedbrain tumor-related symptomsunless
there was a particular note (see also Supplemental Experimental Procedures).
Hematoxylin and Eosin Staining and Immunohistochemistry
Mouse brains were prepared for paraffin and sectioning and stained with
hematoxylin and eosin as described previously (Hambardzumyan et al.,
2009; Holland et al., 2000). Briefly, immunohistochemical staining was per-
formed with an automated staining processor (Hambardzumyan et al.,
2008). The antibodies used in this study are described in the Supplemental
Experimental Procedures. The histological diagnosis and tumor grade was es-
tablished based on the World Health Organization (WHO) criteria (Huse et al.,
2009; Louis et al., 2007).
Western Blot Analysis
Cells were cultured, lysed with NF1 lysis buffer (Yunoue et al., 2003), and
processed for Western blotting by standard methods. The antibodies used
in this study are described in the Supplemental Experimental Procedures.
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